Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › MD › Baltimore › NPI 1790700904
Hospital

Johns Hopkins Bayview Medical Center INC

Johns Hopkins Bayview Medical Center INC was paid $9.20M by Medicaid between Jan 2018 and Dec 2024, across 173 billing codes. Its largest line is 99285, emergency room visit (most serious) — 18% of everything it billed.

33Billing provider infoJOHNS HOPKINS BAYVIEW MEDICAL CENTER INC
BALTIMORE, MD 21224
33aNPI1790700904assigned 07/12/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$9.20M
24GClaims329,591
24DCodes billed173
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other General Acute Care Hospital providers in Maryland

Rank by total paid#5 of 69
Median peer was paid$870K
This provider vs. median11×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$100K$200K$300K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201875,957$2.46M
201956,348$1.05M
202029,298$1.02M
202142,251$1.25M
202248,789$1.31M
202344,979$1.19M
2024incomplete31,969$916K
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99285 Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life 18% 5,802 5,055 $1.65M
90834 Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient 13% 20,149 11,191 $1.19M
G0463 Hospital outpatient clinic visit for assessment and management of a patient 13% 54,524 43,345 $1.18M
90837 Psychotherapy session, about an hourPsychotherapy, 53 minutes with patient 9.1% 8,793 4,688 $837K
99284 Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity 8.0% 4,037 3,425 $737K
G0378 Hospital observation service, per hour 6.6% 1,240 1,054 $608K
90832 Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient 3.5% 6,293 4,926 $321K
99283 Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity 2.7% 2,481 2,126 $244K
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion 2.5% 4,819 1,634 $233K
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward 2.3% 1,078 633 $214K
96413 Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance 2.3% 1,476 1,034 $213K
93306 Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete 1.8% 919 872 $165K
161 more codes
80053 Comprehensive metabolic panel 1.8% 16,358 $164K
99211 Office or other outpatient visit for the evaluation and management of an established patient, minimal severity 1.6% 1,829 $147K
94010 1.2% 529 $108K
99281 Emergency department visit for the evaluation and management, self-limited or minor <1% 3,376 $86K
74177 Computed tomography, abdomen and pelvis; with contrast material <1% 1,519 $76K
20610 <1% 1,443 $73K
71046 Radiologic examination, chest; 2 views <1% 2,989 $55K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 1,284 $52K
97161 <1% 478 $49K
80048 Basic metabolic panel (calcium, ionized) <1% 5,099 $43K
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 16,203 $43K
71260 Computed tomography, thorax, diagnostic; with contrast material <1% 638 $42K
95810 Polysomnography; sleep staging with 4 or more additional parameters <1% 72 $40K
43239 Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple <1% 109 $40K
71250 <1% 626 $35K
92134 <1% 814 $34K
72125 Computed tomography, cervical spine; without contrast material <1% 1,113 $34K
95811 <1% 25 $33K
70450 Computed tomography, head or brain; without contrast material <1% 2,512 $32K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 1,785 $29K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay <1% 2,381 $20K
71045 Radiologic examination, chest; single view <1% 1,931 $18K
99282 Emergency department visit for the evaluation and management, low to moderate severity <1% 231 $17K
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit) <1% 4,136 $16K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 366 $16K
71275 Computed tomographic angiography, chest, with contrast material <1% 146 $16K
36415 Collection of venous blood by venipuncture <1% 8,092 $16K
93922 <1% 66 $13K
97530 Therapeutic activities, direct patient contact, each 15 minutes <1% 587 $13K
J3490 Unclassified drugs <1% 2,718 $12K
87086 Culture, bacterial; quantitative colony count, urine <1% 1,460 $12K
82962 <1% 6,184 $11K
97162 <1% 80 $11K
81001 <1% 4,480 $10K
87631 <1% 504 $10K
73560 <1% 401 $10K
73030 <1% 149 $9K
90715 <1% 287 $8K
84484 <1% 6,538 $8K
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies <1% 617 $7K
90853 Group psychotherapy (other than of a multiple-family group) <1% 1,173 $7K
94060 <1% 21 $7K
87070 <1% 69 $7K
85027 <1% 3,086 $6K
86850 <1% 1,098 $5K
93971 <1% 43 $5K
73502 <1% 17 $4K
83036 Hemoglobin; glycosylated (A1C) <1% 2,900 $4K
J2704 Injection, propofol, 10 mg <1% 3,655 $4K
80069 <1% 112 $4K
A9270 Non-covered item or service <1% 32,466 $4K
J7120 Ringers lactate infusion, up to 1000 cc <1% 4,449 $4K
80061 Lipid panel <1% 1,498 $4K
G2067 Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a medicare-enrolled opioid treatment program) <1% 24 $3K
85610 <1% 3,504 $3K
73110 <1% 38 $3K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r <1% 1,528 $3K
73630 <1% 125 $3K
J7030 Infusion, normal saline solution , 1000 cc <1% 3,569 $3K
97140 Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) <1% 627 $3K
87077 <1% 105 $3K
J2001 Injection, lidocaine hcl for intravenous infusion, 10 mg <1% 3,572 $3K
86140 <1% 1,160 $3K
82803 <1% 855 $2K
90686 <1% 622 $2K
73610 <1% 85 $2K
J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg <1% 1,237 $2K
74176 Computed tomography, abdomen and pelvis; without contrast material <1% 48 $2K
90677 <1% 29 $2K
85018 <1% 138 $2K
92557 <1% 12 $2K
90662 <1% 637 $2K
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour <1% 85 $1K
97116 <1% 147 $1K
94727 <1% 397 $1K
C1769 Guide wire <1% 213 $1K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed <1% 524 $1K
G0108 Diabetes outpatient self-management training services, individual, per 30 minutes <1% 13 $1K
J2270 Injection, morphine sulfate, up to 10 mg <1% 648 $1K
73130 <1% 32 $1K
94729 <1% 628 $1K
97165 <1% 37 $1K
J0690 Injection, cefazolin sodium, 500 mg <1% 1,083 $1K
G8987 Self care functional limitation, current status, at therapy episode outset and at reporting intervals <1% 61 $1K
92083 <1% 13 $999.60
83605 <1% 1,989 $927.53
G8978 Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals <1% 413 $845.07
81002 <1% 260 $812.94
82728 <1% 151 $725.79
J1644 Injection, heparin sodium, per 1000 units <1% 1,167 $720.33
83880 <1% 2,672 $677.94
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 1,173 $670.37
97112 Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination <1% 49 $667.79
96375 Therapeutic injection; each additional sequential IV push <1% 33 $662.40
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 2,805 $626.67
J3010 Injection, fentanyl citrate, 0.1 mg <1% 2,541 $610.90
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV <1% 1,016 $605.67
J3535 Drug administered through a metered dose inhaler <1% 27 $489.38
86900 <1% 873 $481.10
83735 <1% 4,834 $437.42
J1815 Injection, insulin, per 5 units <1% 340 $428.21
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets <1% 14 $425.55
84439 <1% 702 $424.23
J2370 Injection, phenylephrine hcl, up to 1 ml <1% 177 $408.19
84443 Thyroid stimulating hormone (TSH) <1% 2,434 $313.10
J2250 Injection, midazolam hydrochloride, per 1 mg <1% 1,772 $295.64
83690 <1% 1,879 $294.82
J2710 Injection, neostigmine methylsulfate, up to 0.5 mg <1% 16 $273.66
J3475 Injection, magnesium sulfate, per 500 mg <1% 38 $247.12
J1170 Injection, hydromorphone, up to 4 mg <1% 202 $198.15
Q0162 Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen <1% 606 $173.58
70486 <1% 13 $166.49
84703 <1% 96 $166.43
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 1,780 $160.51
84702 <1% 330 $156.82
86901 <1% 872 $151.76
82330 <1% 67 $141.15
Q0163 Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen <1% 1,214 $129.58
85730 <1% 1,315 $127.83
J0696 Injection, ceftriaxone sodium, per 250 mg <1% 126 $121.36
84132 <1% 1,239 $117.35
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 941 $101.57
82947 <1% 69 $96.76
85651 <1% 526 $94.88
82607 <1% 26 $93.48
82077 <1% 213 $88.66
J1200 Injection, diphenhydramine hcl, up to 50 mg <1% 509 $84.21
J2060 Injection, lorazepam, 2 mg <1% 109 $78.69
82043 <1% 228 $76.66
J2765 Injection, metoclopramide hcl, up to 10 mg <1% 110 $74.43
97535 Self-care/home management training, each 15 minutes <1% 18 $67.29
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 507 $64.27
82565 <1% 302 $60.39
82150 <1% 57 $56.78
83540 <1% 288 $38.49
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe <1% 27 $38.29
84466 <1% 314 $31.87
81025 <1% 14 $28.17
J7512 Prednisone, immediate release or delayed release, oral, 1 mg <1% 74 $25.93
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe <1% 25 $19.15
J7050 Infusion, normal saline solution, 250 cc <1% 517 $5.14
84100 <1% 457 $4.07
84295 <1% 115 $3.71
82435 <1% 25 $3.71
J2930 Injection, methylprednisolone sodium succinate, up to 125 mg <1% 14 $0.65
J0665 Injection, bupivicaine, not otherwise specified, 0.5 mg <1% 252 $0.47
G8979 Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting <1% 350 $0.04
G8990 Other physical or occupational therapy primary functional limitation, current status, at therapy episode outset and at reporting intervals <1% 15 $0.01
G8991 Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting <1% 15 $0.01
G1012 Clinical decision support mechanism agilemd, as defined by the medicare appropriate use criteria program 0% 2,385 $0.00
82948 0% 179 $0.00
83970 0% 69 $0.00
90656 0% 35 $0.00
85652 0% 384 $0.00
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 0% 697 $0.00
85379 0% 216 $0.00
J0131 Injection, acetaminophen, not otherwise specified,10 mg 0% 13 $0.00
G8988 Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting 0% 28 $0.00
96415 0% 27 $0.00
J2371 Injection, phenylephrine hydrochloride, 20 micrograms 0% 35 $0.00
J2003 Injection, lidocaine hydrochloride, 1 mg 0% 22 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialNICKOLES, JENNIFER (PRESIDENT)
Same official

Other billing entities under NICKOLES, JENNIFER

Full network →
ProviderLocationPaid
Johns Hopkins Bayview Medical CenterBaltimore, MD$8.51M
Johns Hopkins Bayview Medical CenterBaltimore, MD$7.87M
Johns Hopkins Bayview Med CTR INCBaltimore, MD$4.29M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.